Controlled ovarian stimulation – European Clinical Trials Information Network

Study on Ovarian Stimulation Using Follitropin Delta and Dydrogesterone for Women Donating Eggs

Wed, 29 Apr 2026 15:05:43 +0000

This clinical trial is focused on studying the effects of a treatment involving two medications, Follitropin delta and Dydrogesterone, on women who are donating their eggs. The study aims to understand how these medications affect the number of egg cells that can be collected from the donors. Follitropin delta is a type of hormone used to stimulate the ovaries, while Dydrogesterone is a hormone that helps prepare the body for pregnancy. The trial will explore how these medications work together during different phases of the menstrual cycle to enhance egg production.

Participants in the study will receive Follitropin delta as a solution for injection, which is administered under the skin using a pre-filled pen. Dydrogesterone will be taken orally in the form of film-coated tablets. The study will compare the effects of these medications when used during the typical follicular phase, which is the first half of the menstrual cycle, and the luteal phase, which is the second half. The goal is to determine the best approach for maximizing the number of egg cells that can be retrieved from donors.

The trial will last for a specific period, during which participants will follow a treatment plan that includes both medications. The study will monitor various factors, such as the number of egg cells collected, the hormonal changes in the body, and the duration of the treatment. This research is important for improving the process of egg donation and could potentially benefit women who are undergoing fertility treatments in the future.

Study Comparing Progesterone and Ganirelix for Preventing LH Surge in Women Undergoing Ovarian Stimulation for Egg Donation

Wed, 29 Apr 2026 15:05:21 +0000

This clinical trial is focused on women who are undergoing ovarian stimulation as part of an oocyte donation process. The study is investigating the effectiveness of two different treatments in preventing a surge in a hormone called luteinizing hormone (LH) during this process. The treatments being compared are micronized natural progesterone (known as Seidigestan) and a type of medication called gonadotropin-releasing hormone (GnRH) antagonists, specifically Astarté. The main goal is to see if the progesterone treatment is not less effective than the GnRH antagonist treatment.

Participants in the study will receive one of the two treatments. Seidigestan is taken orally in the form of soft capsules, while Astarté is administered as a solution for injection. The study will monitor the number of mature eggs, known as oocytes, that are obtained during the ovarian stimulation process. This will help determine which treatment is more effective in managing the hormone levels during the procedure.

The study will take place over a period of time, with participants receiving their assigned treatment and undergoing regular monitoring to assess the outcomes. The results will provide valuable information on the best approach to prevent LH surges during controlled ovarian stimulation, which is an important aspect of successful oocyte donation. The findings could potentially improve the protocols used in fertility treatments and oocyte donation programs.

Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

Wed, 29 Apr 2026 14:25:06 +0000

This clinical trial is focused on studying infertility in women who are undergoing assisted reproductive technologies, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The trial aims to compare the ovarian response, which is how the ovaries react, after controlled ovarian stimulation using different mixed protocols of two medications: REKOVELLE and MENOPUR. These medications are used to stimulate the ovaries to produce eggs.

The study involves several medications that are administered as injections. REKOVELLE contains the active substance follitropin delta, while MENOPUR contains menotrophin. Other medications used in the study include Fyremadel with the active substance ganirelix, Decapeptyl with triptorelin acetate, and Ovitrelle with choriogonadotropin alfa. These medications are given through subcutaneous injections, which means they are injected under the skin.

Participants in the study will receive these medications over a period of time to stimulate their ovaries. The main goal is to observe the number of fertilized eggs, known as oocytes, after insemination. The study is designed to be randomised, meaning participants are randomly assigned to different treatment groups, and it is controlled, which means it includes a comparison group. The trial is also assessor-blind, meaning the people assessing the outcomes do not know which treatment the participants received, to ensure unbiased results.